Physician profile
Daniel Kramer
NPI 1447647177
$2,680.90
in general payments reported to CMS, 2019-2025
18 companies · $414 in 2025
The $414 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $116 · 2021: $140 · 2022: $199 · 2023: $898 · 2024: $914 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,225.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $932.89 | 2020-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $489.98 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $302.88 | 2023-2025 | Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.53 | 2022-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genentech USA, INC. | $170.76 | 2022-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $125.24 | 2023-2025 | Dupixent |
| Breas Medical, INC. | $97.93 | 2024 | Vivo 45 Ls |
| Amgen INC. | $87.35 | 2023-2024 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $43.44 | 2023 | |
| Pulmonx Corporation | $36.45 | 2023-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Sanofi Pasteur INC. | $27.21 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.70 | 2024 | Aralast |
| Boston Scientific Corporation | $19.70 | 2021 | |
| Baxter Healthcare | $18.67 | 2023 | Hillrom - Life 2000 Ventilation System |
| Electromed, INC. | $18.32 | 2024 | Smartvest |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $17.64 | 2024 | Arikayce |
| Merck Sharp & Dohme LLC | $16.74 | 2024 | Zerbaxa, Recarbrio |
| Tactile Systems Technology INC | $12.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.